BioLife Solutions (NASDAQ:BLFS) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of BioLife Solutions (NASDAQ:BLFS - Free Report) from a sell rating to a hold rating in a research note published on Wednesday.

Several other equities analysts have also recently weighed in on BLFS. Benchmark restated a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. HC Wainwright increased their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Finally, Northland Securities upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, BioLife Solutions presently has a consensus rating of "Moderate Buy" and an average price target of $29.86.

BioLife Solutions Stock Down 0.3 %

NASDAQ BLFS traded down $0.07 during trading on Wednesday, hitting $24.99. The stock had a trading volume of 569,608 shares, compared to its average volume of 350,621. BioLife Solutions has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company's 50-day moving average price is $26.40 and its two-hundred day moving average price is $25.49. The company has a market capitalization of $1.17 billion, a PE ratio of -23.58 and a beta of 2.04.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. As a group, sell-side analysts forecast that BioLife Solutions will post -0.3 EPS for the current year.

Insider Transactions at BioLife Solutions

In other news, CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now directly owns 121,779 shares of the company's stock, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sarah Aebersold sold 5,632 shares of BioLife Solutions stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72. Following the sale, the insider now directly owns 45,860 shares of the company's stock, valued at $1,144,665.60. The trade was a 10.94 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,117 shares of company stock worth $534,442. 2.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. D.A. Davidson & CO. grew its position in shares of BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock valued at $1,069,000 after purchasing an additional 519 shares during the last quarter. Stifel Financial Corp boosted its stake in BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock valued at $325,000 after purchasing an additional 670 shares during the period. 1620 Investment Advisors Inc. grew its holdings in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares in the last quarter. Smartleaf Asset Management LLC increased its position in BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after buying an additional 950 shares during the period. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions during the fourth quarter worth $26,000. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.